{"id":"W4387810740","doi":"10.1016/j.annonc.2023.09.2406","title":"1373P Efficacy and safety of taletrectinib in patients (Pts) with ROS1+ non-small cell lung cancer (NSCLC): Interim analysis of global TRUST-II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Cilag; Chugai Pharmaceutical; BeiGene; Ipsen; Merck Sharp and Dohme; Eisai; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Daiichi-Sankyo; Amgen; Pfizer; Mesothelioma Applied Research Foundation","keywords":"ROS1; Medicine; Interim; Internal medicine; Interim analysis; Oncology; Lung cancer; Cancer; Clinical trial; Adenocarcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001368782,0.0006415093,0.001474942,0.0002128774,0.0001474062,0.001096848,0.0004049732,0.0004390192,0.002372045],"category_scores_gemma":[0.001150476,0.0002496133,0.002363779,0.0004871083,0.000363377,0.0007994426,0.0004309215,0.001352723,0.0005634452],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008131163,"about_ca_system_score_gemma":0.0006409682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001187823,"about_ca_topic_score_gemma":0.002729462,"domain_scores_codex":[0.999429,0.0002224013,0.00002724275,0.0001134433,0.00007995163,0.0001278229],"domain_scores_gemma":[0.999414,0.0001180368,0.0001945389,0.00008505664,0.00006847,0.0001199066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5941352,0.001792541,0.2026016,0.001047876,0.01767322,0.0003837177,0.0001801545,0.0102365,0.01611901,0.0008136958,0.01044874,0.1445677],"study_design_scores_gemma":[0.10068,0.1162478,0.7283241,0.0002172634,0.02283096,0.001021732,0.0003686068,0.00791072,0.008144913,0.0016987,0.01235317,0.0002019646],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904607,0.002219273,0.000441387,0.0002942453,0.00005114398,0.00009166134,0.003899689,0.00006201164,0.002479858],"genre_scores_gemma":[0.9922275,0.0004553741,0.000216624,0.0002483043,0.00003656113,0.00007285972,0.005387785,0.00002973921,0.0013252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002372045,"threshold_uncertainty_score":0.007935345,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03036739517946768,"score_gpt":0.4112892430959512,"score_spread":0.3809218479164835,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}